https://scholars.lib.ntu.edu.tw/handle/123456789/393915
標題: | Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs | 作者: | Locarnini, Stephen Hatzakis, Angelos DING-SHINN CHEN Lok, Anna |
關鍵字: | Acute hepatitis B; Chronic hepatitis B; Chronic liver disease; Epidemiology; Hepatitis B vaccine; Hepatocellular carcinoma; Prevention; Public policy; Treatment; WHO | 公開日期: | 2015 | 卷: | 62 | 期: | S1 | 起(迄)頁: | S76-S86 | 來源出版物: | Journal of Hepatology | 摘要: | The last 50 years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free. ? 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. |
URI: | http://www.scopus.com/inward/record.url?eid=2-s2.0-84934335209&partnerID=MN8TOARS http://scholars.lib.ntu.edu.tw/handle/123456789/393915 |
DOI: | 10.1016/j.jhep.2015.01.018 | SDG/關鍵字: | antivirus agent; hepatitis B surface antigen; hepatitis B vaccine; interferon; nucleoside analog; hepatitis B surface antigen; hepatitis B vaccine; hepatitis B(e) antigen; interferon; antiviral therapy; chronic hepatitis B; drug efficacy; drug safety; health care policy; hepatitis B; human; incidence; infection control; liver cell carcinoma; nonhuman; prevalence; priority journal; randomized controlled trial (topic); Review; treatment indication; treatment outcome; vaccination; world health organization; blood; hepatitis B; immunology; policy; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Humans; Interferons; Public Policy; Vaccination |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。